Clinical response to cancer immunotherapies such as PD-(L)1 inhibitors is associated with the priming of sufficient levels of tumor infiltrating CD8+ T cells to mount a durable anti-tumor response. However, many cancer patients display poor T cell infiltration or deficiencies in T cell priming. There is therefore a clear unmet clinical need for new therapies that can expand the repertoire of tumor neoantigen specific T cells and increase treatment response rates. CD40 bispecific antibodies (bsAbs) provide a new opportunity to achieve more efficient tumor specific T cell priming. Furthermore, CD40 bsAb based therapies also target macrophages/myeloid cells, which may provide important benefits when combining with other treatment modalities.